Income Statement Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Equities

600276

CNE0000014W7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 22/01/2026			5-day change	1st Jan Change
59.44 ^CNY	-1.10%		-6.56%	-0.22%

01-13	Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug	MT
01-13	Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation	MT

cbd80a8e960aa2.rTPIEu4cWU9ViJgEUr7FOR_3mp6qJuniHIyHx0Xpyx8.2wuRRp8kPwFk4PR2OomBdFiP8Ovlbb2tbrnRig2A_EnUAf5am20wDRD71Q

Published financial data: JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	27.61B	25.78B	21.21B	22.38B	25.01B
Other Revenues, Total	122M	125M	62.25M	443M	2.98B
Total Revenues	27.73B	25.91B	21.28B	22.82B	27.98B
Cost of Goods Sold, Total	3.36B	3.76B	3.5B	3.56B	3.88B
Gross Profit	24.38B	22.15B	17.77B	19.26B	24.1B
Selling General & Admin Expenses, Total	12.87B	12.24B	9.65B	9.99B	10.89B
Provision for Bad Debts	9.36M	-3.87M	26.02M	-15.77M	-28.67M
R&D Expenses	4.99B	5.94B	4.89B	4.95B	6.58B
Other Operating Expenses	239M	190M	190M	149M	182M
Other Operating Expenses, Total	18.11B	18.37B	14.76B	15.08B	17.63B
Operating Income	6.27B	3.78B	3.01B	4.18B	6.48B
Interest Expense, Total	-	-4.71M	-6.49M	-5.9M	-5.56M
Interest And Investment Income	632M	581M	773M	477M	608M
Net Interest Expenses	632M	576M	766M	471M	602M
Currency Exchange Gains (Loss)	-102M	-22.42M	93.19M	7.9M	-24.04M
Other Non Operating Income (Expenses)	-3.89M	-2.2M	-1.37M	736K	-612K
EBT, Excl. Unusual Items	6.8B	4.33B	3.87B	4.66B	7.05B
Gain (Loss) On Sale Of Investments	16.5M	36.23M	76.5M	-107M	109M
Gain (Loss) On Sale Of Assets	699K	3.37M	4.23M	-3.05M	5.4M
Asset Writedown	-	-1.73M	-130M	-70M	-4.94M
Other Unusual Items	80.67M	101M	145M	192M	7.55M
EBT, Incl. Unusual Items	6.9B	4.47B	3.97B	4.67B	7.17B
Income Tax Expense	587M	-17.72M	153M	389M	833M
Earnings From Continuing Operations	6.31B	4.48B	3.82B	4.28B	6.34B
Net Income to Company	6.31B	4.48B	3.82B	4.28B	6.34B
Minority Interest	19.49M	46.19M	91.23M	24.62M	-468K
Net Income - (IS)	6.33B	4.53B	3.91B	4.3B	6.34B
Net Income to Common Incl Extra Items	6.33B	4.53B	3.91B	4.3B	6.34B
Net Income to Common Excl. Extra Items	6.33B	4.53B	3.91B	4.3B	6.34B
Per Share Items
Net EPS - Basic	0.99	0.71	0.61	0.68	1
Basic EPS - Continuing Operations	0.99	0.71	0.61	0.68	1
Basic Weighted Average Shares Outstanding	6.38B	6.38B	6.4B	6.33B	6.34B
Net EPS - Diluted	0.99	0.71	0.61	0.68	1
Diluted EPS - Continuing Operations	0.99	0.71	0.61	0.68	1
Diluted Weighted Average Shares Outstanding	6.38B	6.38B	6.4B	6.33B	6.34B
Normalized Basic EPS	0.67	0.43	0.39	0.46	0.7
Normalized Diluted EPS	0.67	0.43	0.39	0.46	0.7
Dividend Per Share	0.17	0.16	0.16	0.2	0.2
Payout Ratio	16.07	23.54	26	23.77	20.12
American Depositary Receipts Ratio (ADR)	2	2	2	2	2
Supplemental Items
EBITDA	6.72B	4.27B	3.55B	4.83B	7.19B
EBITA	6.28B	3.79B	3.03B	4.2B	6.54B
EBIT	6.27B	3.78B	3.01B	4.18B	6.48B
EBITDAR	6.73B	4.31B	3.56B	4.87B	7.31B
Total Revenues (As Reported)	27.73B	25.91B	21.28B	22.82B	27.98B
Effective Tax Rate - (Ratio)	8.51	-0.4	3.87	8.34	11.61
Total Current Taxes	568M	75.66M	176M	488M	856M
Total Deferred Taxes	18.79M	-93.38M	-22.17M	-98.47M	-23.14M
Normalized Net Income	4.27B	2.75B	2.51B	2.93B	4.41B
Interest on Long-Term Debt	-	4.71M	5.55M	4.27M	4.54M
Non-Cash Pension Expense	-	-	125M	17.18M	88.83M
Supplemental Operating Expense Items
Marketing Expenses	-	-	-	-	-
Selling and Marketing Expenses	9.8B	9.38B	7.35B	7.58B	8.34B
General and Administrative Expenses	3.07B	2.86B	2.31B	2.42B	2.56B
Research And Development Expense From Footnotes	4.99B	5.94B	4.89B	4.95B	6.58B
Net Rental Expense, Total	13.24M	41.53M	15.95M	42.58M	120M
Imputed Operating Lease Interest Expense	-	-	1.1M	2.8M	57.51M
Imputed Operating Lease Depreciation	-	-	14.85M	39.78M	62.33M
Stock-Based Comp., R&D Exp. (Total)	123M	95.31M	14.79M	78.04M	94.28M
Stock-Based Comp., S&M Exp. (Total)	152M	130M	3.27M	57.75M	69.98M
Stock-Based Comp., G&A Exp. (Total)	38.57M	24.25M	3.27M	17.43M	25.65M
Stock-Based Comp., Other (Total)	19.53M	28.26M	10.74M	13.44M	19.34M
Total Stock-Based Compensation	332M	278M	32.06M	167M	209M

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	10.8B	13.63B	15.11B	20.75B	24.82B
Short Term Investments	-	-	-	-	-
Trading Asset Securities, Total	5.63B	5.09B	2.76B	99.05M	273M
Total Cash And Short Term Investments	16.43B	18.72B	17.87B	20.85B	25.09B
Accounts Receivable, Total	8.18B	6.88B	8.34B	6.13B	6.16B
Other Receivables	651M	658M	562M	438M	66.41M
Total Receivables	8.83B	7.54B	8.9B	6.57B	6.23B
Inventory	1.78B	2.4B	2.45B	2.31B	2.42B
Prepaid Expenses	410M	432M	507M	226M	240M
Other Current Assets, Total	602M	1.09B	1.2B	1.33B	1.34B
Total Current Assets	28.05B	30.19B	30.93B	31.29B	35.31B
Gross Property Plant And Equipment	7.51B	9.66B	10.58B	11.05B	11.98B
Accumulated Depreciation	-2.92B	-3.38B	-3.9B	-4.42B	-5.05B
Net Property Plant And Equipment	4.59B	6.28B	6.68B	6.63B	6.93B
Long-term Investments	1.5B	1B	1.51B	1.45B	1.73B
Other Intangibles, Total	341M	442M	520M	884M	1.19B
Deferred Tax Assets Long-Term	52.97M	141M	223M	321M	377M
Deferred Charges Long-Term	198M	569M	2.05B	2.83B	4.11B
Other Long-Term Assets, Total	-	649M	443M	383M	479M
Total Assets	34.73B	39.27B	42.36B	43.78B	50.14B
Liabilities
Accounts Payable, Total	1.43B	1.92B	1.49B	1.33B	1.52B
Accrued Expenses, Total	131M	166M	97.57M	140M	941M
Short-term Borrowings	-	-	1.26B	-	-
Current Portion of Long-Term Debt	-	-	-	-	-
Current Portion of Leases	-	-	-	-	41.13M
Current Income Taxes Payable	25.14M	21.77M	4.03M	59.28M	243M
Unearned Revenue Current, Total	358M	220M	187M	198M	160M
Other Current Liabilities	1.83B	1.07B	596M	822M	731M
Total Current Liabilities	3.77B	3.4B	3.64B	2.55B	3.63B
Long-Term Leases	-	152M	98.86M	75.18M	69.04M
Unearned Revenue Non Current	141M	117M	119M	38.95M	226M
Deferred Tax Liability Non Current	29.76M	24.77M	84.33M	83.64M	117M
Total Liabilities	3.94B	3.69B	3.94B	2.75B	4.05B
Common Stock, Total	5.33B	6.4B	6.38B	6.38B	6.38B
Additional Paid In Capital	3.14B	3.36B	3.02B	3.06B	3.19B
Retained Earnings	23.53B	25.93B	28.82B	32.1B	37.16B
Treasury Stock	-1.5B	-665M	-398M	-1.09B	-1.23B
Comprehensive Income and Other	-4.79M	-12.16M	3.23M	19.32M	16.97M
Total Common Equity	30.5B	35B	37.82B	40.47B	45.52B
Minority Interest	283M	569M	589M	567M	570M
Total Equity	30.79B	35.57B	38.41B	41.03B	46.09B
Total Liabilities And Equity	34.73B	39.27B	42.36B	43.78B	50.14B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	6.35B	6.38B	6.37B	6.36B	6.36B
ECS Total Common Shares Outstanding	6.35B	6.38B	6.37B	6.36B	6.36B
Book Value / Share	4.8	5.48	5.94	6.36	7.16
Tangible Book Value	30.16B	34.56B	37.3B	39.58B	44.33B
Tangible Book Value Per Share	4.75	5.42	5.86	6.22	6.97
Total Debt	0	152M	1.36B	75.18M	110M
Net Debt	-16.43B	-18.57B	-16.51B	-20.77B	-24.98B
Debt Equivalent Oper. Leases	106M	332M	128M	341M	959M
Minority Interest, Total (Incl. Fin. Div)	283M	569M	589M	567M	570M
Equity Method Investments, Total	60M	193M	768M	695M	666M
Account Code - Inventory Valuation	6	6	6	6	6
Inventories - Raw Materials, Total	577M	968M	875M	766M	723M
Inventories - Work In Process, Total	250M	410M	430M	414M	445M
Inventories - Finished Goods, Total	969M	1.05B	1.18B	1.17B	1.3B
Buildings, Total	2.14B	2.7B	3.54B	3.85B	3.97B
Machinery, Total	4.06B	5.12B	5.68B	5.97B	6.1B
Full Time Employees	28.9K	24.49K	20.64K	19.61K	20.24K
Accumulated Allowance for Doubtful Accounts (Supple)	77.08M	72.03M	98.04M	82.27M	53.61M

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	6.33B	4.53B	3.91B	4.3B	6.34B
Depreciation & Amortization - CF	439M	509M	555M	667M	709M
Amortization of Goodwill and Intangible Assets - (CF)	8.95M	10.15M	13.85M	26.03M	63.43M
Depreciation & Amortization, Total	448M	519M	569M	693M	772M
Amortization of Deferred Charges, Total - (CF)	27.35M	21.66M	74.89M	101M	98.62M
(Gain) Loss From Sale Of Asset	-699K	-3.37M	-5.47M	-3.16M	-5.4M
(Gain) Loss on Sale of Investments - (CF)	-358M	-170M	-431M	35.62M	-132M
Asset Writedown & Restructuring Costs	-3.35M	-118M	-102M	76.21M	4.94M
Provision and Write-off of Bad Debts	9.36M	-3.87M	26.02M	-15.77M	-28.67M
Other Operating Activities, Total	-14.88M	-27.8M	62.21M	17.02M	30.83M
Change In Accounts Receivable	-3.49B	-868M	-2.28B	2.04B	-376M
Change In Inventories	-174M	-631M	-52.68M	129M	-136M
Change In Accounts Payable	222M	810M	-511M	315M	671M
Change In Deferred Taxes	18.79M	-93.38M	-22.11M	-98.47M	-23.14M
Change in Other Net Operating Assets	414M	253M	34.98M	55.47M	209M
Cash from Operations	3.43B	4.22B	1.27B	7.64B	7.42B
Capital Expenditure	-554M	-1.66B	-1.99B	-1.48B	-1.97B
Sale of Property, Plant, and Equipment	3.56M	16.11M	20.21M	20.18M	21.9M
Divestitures	-	-	36.05M	-	-
Investment in Marketable and Equity Securities, Total	2.01B	842M	2.16B	2.59B	-17.2M
Other Investing Activities, Total	341M	260M	166M	95.51M	52.51M
Cash from Investing	1.8B	-546M	390M	1.22B	-1.91B
Short Term Debt Issued, Total	-	-	1.26B	21.1M	-
Long-Term Debt Issued, Total	-	-	-	-	800M
Total Debt Issued	-	-	1.26B	21.1M	800M
Short Term Debt Repaid, Total	-	-	-	-1.28B	-
Long-Term Debt Repaid, Total	-	-31.05M	-36.28M	-34.33M	-847M
Total Debt Repaid	-	-31.05M	-36.28M	-1.32B	-847M
Issuance of Common Stock	1.17B	-	-	-	-
Repurchase of Common Stock	-11.98M	-235M	-1.07B	-827M	-228M
Common Dividends Paid	-1.02B	-1.07B	-1.02B	-1.02B	-1.27B
Common & Preferred Stock Dividends Paid	-1.02B	-1.07B	-1.02B	-1.02B	-1.27B
Other Financing Activities, Total	149M	334M	539M	-	-
Cash from Financing	291M	-998M	-319M	-3.14B	-1.55B
Foreign Exchange Rate Adjustments	-89.08M	-16.87M	80.5M	12.53M	7.4M
Net Change in Cash	5.43B	2.66B	1.42B	5.73B	3.97B
Supplemental Items
Cash Income Tax Paid (Refund)	3.02B	1.61B	1.63B	1.57B	2.29B
Levered Free Cash Flow	2.6B	1.29B	-2.06B	4.88B	4.41B
Unlevered Free Cash Flow	2.6B	1.29B	-2.05B	4.88B	4.41B
Change In Net Working Capital	1.57B	219M	2.62B	-2.8B	-1.26B
Net Debt Issued / Repaid	-	-31.05M	1.22B	-1.29B	-47.38M

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	12.59	6.38	4.62	6.06	8.62
Return on Total Capital	14.07	7.1	4.99	6.45	9.27
Return On Equity %	22.64	13.51	10.31	10.77	14.55
Return on Common Equity	22.9	13.83	10.73	10.99	14.74
Margin Analysis
Gross Profit Margin %	87.9	85.5	83.53	84.39	86.13
SG&A Margin	46.4	47.26	45.38	43.8	38.92
EBITDA Margin %	24.23	16.49	16.66	21.17	25.71
EBITA Margin %	22.65	14.62	14.23	18.41	23.37
EBIT Margin %	22.61	14.58	14.17	18.3	23.14
Income From Continuing Operations Margin %	22.75	17.31	17.93	18.75	22.64
Net Income Margin %	22.82	17.49	18.36	18.85	22.64
Net Avail. For Common Margin %	22.82	17.49	18.36	18.85	22.64
Normalized Net Income Margin	15.39	10.62	11.81	12.86	15.75
Levered Free Cash Flow Margin	9.39	4.99	-9.66	21.38	15.76
Unlevered Free Cash Flow Margin	9.39	5	-9.64	21.4	15.77
Asset Turnover
Asset Turnover	0.89	0.7	0.52	0.53	0.6
Fixed Assets Turnover	6.41	4.77	3.29	3.43	4.13
Receivables Turnover (Average Receivables)	4.06	3.42	2.79	3.09	4.07
Inventory Turnover (Average Inventory)	1.98	1.8	1.44	1.5	1.64
Short Term Liquidity
Current Ratio	7.44	8.87	8.5	12.25	9.72
Quick Ratio	6.7	7.72	7.36	10.74	8.62
Operating Cash Flow to Current Liabilities	0.91	1.24	0.35	2.99	2.04
Days Sales Outstanding (Average Receivables)	90.2	106.61	130.99	118.06	89.96
Days Outstanding Inventory (Average Inventory)	184.58	203.16	252.82	244.08	223.1
Average Days Payable Outstanding	141.22	127.97	175.43	150.62	130.98
Cash Conversion Cycle (Average Days)	133.56	181.8	208.38	211.53	182.08
Long Term Solvency
Total Debt/Equity	-	0.43	3.54	0.18	0.24
Total Debt / Total Capital	-	0.42	3.42	0.18	0.24
LT Debt/Equity	-	0.43	0.26	0.18	0.15
Long-Term Debt / Total Capital	-	0.42	0.25	0.18	0.15
Total Liabilities / Total Assets	11.35	9.41	9.31	6.28	8.07
EBIT / Interest Expense	-	801.73	464.37	707.35	1.16K
EBITDA / Interest Expense	-	911.93	552.06	824.66	1.3K
(EBITDA - Capex) / Interest Expense	-	558.52	245.19	573.33	949.62
Total Debt / EBITDA	-	0.04	0.38	0.02	0.02
Net Debt / EBITDA	-2.45	-4.32	-4.61	-4.27	-3.45
Total Debt / (EBITDA - Capex)	-	0.06	0.85	0.02	0.02
Net Debt / (EBITDA - Capex)	-2.67	-7.06	-10.37	-6.14	-4.73
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	19.09	-6.6	-17.87	7.26	22.63
Gross Profit, 1 Yr. Growth %	19.68	-9.14	-19.76	8.36	25.17
EBITDA, 1 Yr. Growth %	9.81	-36.45	-16.79	34.22	48.56
EBITA, 1 Yr. Growth %	14.01	-39.71	-19.8	36.33	55.17
EBIT, 1 Yr. Growth %	14	-39.79	-19.92	36.49	55.07
Earnings From Cont. Operations, 1 Yr. Growth %	18.44	-28.93	-14.92	12.13	48.14
Net Income, 1 Yr. Growth %	18.78	-28.41	-13.77	10.14	47.28
Normalized Net Income, 1 Yr. Growth %	16.55	-35.54	-4.17	15.54	50.2
Diluted EPS Before Extra, 1 Yr. Growth %	19.01	-28.28	-14.08	11.48	47.06
Accounts Receivable, 1 Yr. Growth %	50.43	-15.8	21.17	-26.45	0.4
Inventory, 1 Yr. Growth %	10.66	35.13	1.99	-5.57	4.46
Net Property, Plant and Equip., 1 Yr. Growth %	12.53	36.87	6.38	-0.69	4.51
Total Assets, 1 Yr. Growth %	26.03	13.06	7.87	3.34	14.51
Tangible Book Value, 1 Yr. Growth %	23.49	14.58	7.94	6.11	11.99
Common Equity, 1 Yr. Growth %	23.12	14.75	8.06	6.99	12.49
Cash From Operations, 1 Yr. Growth %	-10.08	22.93	-70.01	504.12	-2.89
Capital Expenditures, 1 Yr. Growth %	-1.25	200.3	19.68	-25.52	32.71
Levered Free Cash Flow, 1 Yr. Growth %	-71.45	-49.99	-278.65	-340.33	-9.36
Unlevered Free Cash Flow, 1 Yr. Growth %	-71.45	-49.88	-277.84	-341	-9.36
Dividend Per Share, 1 Yr. Growth %	4.32	-4.02	0	25	0
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	26.19	5.47	-12.42	-6.14	14.69
Gross Profit, 2 Yr. CAGR %	27.15	4.28	-14.62	-6.76	16.46
EBITDA, 2 Yr. CAGR %	23.04	-16.46	-27.37	6.48	41.39
EBITA, 2 Yr. CAGR %	24.28	-17.1	-30.56	5.49	45.66
EBIT, 2 Yr. CAGR %	24.29	-17.15	-30.67	5.32	45.48
Earnings From Cont. Operations, 2 Yr. CAGR %	24.64	-8.25	-22.24	-2.33	28.88
Net Income, 2 Yr. CAGR %	24.76	-7.79	-21.43	-2.55	27.36
Normalized Net Income, 2 Yr. CAGR %	24.04	-13.32	-23.29	5.82	31.74
Diluted EPS Before Extra, 2 Yr. CAGR %	24.59	-7.69	-21.5	-2.14	28.04
Accounts Receivable, 2 Yr. CAGR %	35.83	12.54	1.01	-5.6	-14.07
Inventory, 2 Yr. CAGR %	31.35	22.28	17.4	-1.86	-0.68
Net Property, Plant and Equip., 2 Yr. CAGR %	11.53	24.1	20.66	2.78	1.87
Total Assets, 2 Yr. CAGR %	24.62	19.37	10.43	5.6	8.78
Tangible Book Value, 2 Yr. CAGR %	24.51	18.95	11.21	7.02	9.01
Common Equity, 2 Yr. CAGR %	24.35	18.86	11.35	7.52	9.7
Cash From Operations, 2 Yr. CAGR %	11.22	5.13	-39.28	34.6	142.21
Capital Expenditures, 2 Yr. CAGR %	2.36	72.2	89.57	-5.59	-0.58
Levered Free Cash Flow, 2 Yr. CAGR %	-30.57	-62.36	-10.8	105.93	47.39
Unlevered Free Cash Flow, 2 Yr. CAGR %	-30.57	-62.32	-10.89	105.74	47.59
Dividend Per Share, 2 Yr. CAGR %	14.43	0.06	-2.03	11.8	11.8
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	26.09	14.15	-2.97	-6.29	2.61
Gross Profit, 3 Yr. CAGR %	26.71	13.67	-4.45	-7.56	2.86
EBITDA, 3 Yr. CAGR %	19.96	-1.28	-16.64	-10.42	19.08
EBITA, 3 Yr. CAGR %	20.59	-2.35	-18.08	-12.54	20.09
EBIT, 3 Yr. CAGR %	20.6	-2.38	-18.17	-12.68	19.82
Earnings From Cont. Operations, 3 Yr. CAGR %	24.2	3.36	-10.53	-12.15	12.22
Net Income, 3 Yr. CAGR %	25.3	3.67	-9.83	-12.07	11.83
Normalized Net Income, 3 Yr. CAGR %	24.62	-0.28	-11.81	-11.74	18.92
Diluted EPS Before Extra, 3 Yr. CAGR %	25.35	3.58	-9.88	-11.77	12.09
Accounts Receivable, 3 Yr. CAGR %	25.09	15.81	15.35	-9.13	-3.64
Inventory, 3 Yr. CAGR %	31.07	32.6	15.11	9.18	0.2
Net Property, Plant and Equip., 3 Yr. CAGR %	14.2	19.41	17.89	13.08	3.35
Total Assets, 3 Yr. CAGR %	24.4	20.64	15.41	8.03	8.49
Tangible Book Value, 3 Yr. CAGR %	25.97	21.11	15.16	9.48	8.65
Common Equity, 3 Yr. CAGR %	25.68	21.06	15.15	9.88	9.15
Cash From Operations, 3 Yr. CAGR %	10.45	15	-30.79	30.59	20.72
Capital Expenditures, 3 Yr. CAGR %	13.38	46.53	52.53	38.85	5.76
Levered Free Cash Flow, 3 Yr. CAGR %	5.72	-37.92	-39.14	23.61	56.5
Unlevered Free Cash Flow, 3 Yr. CAGR %	5.72	-37.87	-39.18	23.64	56.41
Dividend Per Share, 3 Yr. CAGR %	42.34	7.92	0.04	6.26	7.72
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	24.38	18.48	8.99	5.55	3.74
Gross Profit, 5 Yr. CAGR %	25.14	18.05	8.2	5.01	3.42
EBITDA, 5 Yr. CAGR %	20.59	6.63	-1.85	1.7	3.29
EBITA, 5 Yr. CAGR %	21.04	5.85	-3.3	0.66	3.49
EBIT, 5 Yr. CAGR %	21.05	5.84	-3.35	0.57	3.31
Earnings From Cont. Operations, 5 Yr. CAGR %	23.19	11.23	2.99	1.04	3.54
Net Income, 5 Yr. CAGR %	23.85	11.84	3.96	1.14	3.53
Normalized Net Income, 5 Yr. CAGR %	22.39	8.32	2.63	1.13	3.78
Diluted EPS Before Extra, 5 Yr. CAGR %	23.71	11.7	3.91	1.25	3.71
Accounts Receivable, 5 Yr. CAGR %	20.06	14.83	14.83	6.72	2.53
Inventory, 5 Yr. CAGR %	27.73	30.43	25.42	17.56	8.51
Net Property, Plant and Equip., 5 Yr. CAGR %	20.97	20.46	16.74	12.46	11.2
Total Assets, 5 Yr. CAGR %	24.75	22.34	18.61	14.38	12.72
Tangible Book Value, 5 Yr. CAGR %	25.38	23.35	19.85	15.26	12.66
Common Equity, 5 Yr. CAGR %	25.16	23.09	19.74	15.45	12.94
Cash From Operations, 5 Yr. CAGR %	8.55	10.23	-13.06	22.47	14.23
Capital Expenditures, 5 Yr. CAGR %	7.06	8.42	39.26	22.9	28.53
Levered Free Cash Flow, 5 Yr. CAGR %	18.99	18.35	-1.38	-2.01	-13.52
Unlevered Free Cash Flow, 5 Yr. CAGR %	18.99	18.41	-1.42	-1.99	-13.51
Dividend Per Share, 5 Yr. CAGR %	40.09	26.14	22.59	9.46	4.59